Hereditary Angioedema  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hereditary Angioedema
ACTRN12623000736640: An open-label, multiple dose study to compare the single-dose and steady-state pharmacokinetics of a 40 mg PHA-022121 extended-release (XR) tablet administered once daily between healthy Japanese, Chinese, and Caucasian volunteers.

Not yet recruiting
1
36
 
Pharvaris Netherlands B.V., Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
 
 
ACTRN12623000689673: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BW-20805 in Healthy Subjects

Recruiting
1
32
 
Argo Biopharma Australia Pty Ltd, Argo Biopharma Australia Pty Ltd
Hereditary angioedema
 
 
NCT05477160: A Study of STAR-0215 in Healthy Adult Participants

Completed
1
41
US
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Astria Therapeutics, Inc.
Hereditary Angioedema
11/23
11/23
NCT05691361: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Recruiting
1
53
RoW
ADX-324, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc.
Hereditary Angioedema
01/25
12/25

Download Options